BioAgilytix Labs Acquired by Riverside Partners June 4, 2013

June 4, 2013


On June 4, 2013, Riverside Partners, a Boston based private equity firm, announced that it has completed an investment in BioAgilytix Labs (BioAgilytix), a leading contract bioanalytical laboratory specializing in large molecule biologic drugs. BioAgilytix provides outsourced laboratory services to customers within the pharmaceutical, biotechnology, and agriculture industries. Riverside Partners is a private equity partner for leading technology and healthcare companies.


With this acquisition, Riverside Partners will enter the large molecule drug development business, which is a “very exciting area within the pharmaceutical and biotechnology industries,” according to Phillip Borden, General Partner at Riverside Partners. Riverside Partners will utilize its deep healthcare experience to accelerate BioAgilytix’s growth.

Crosstree’s Role

Crosstree Capital Partners served as exclusive financial advisor to BioAgilytix Labs.

Jeff and his colleagues at Crosstree did an exceptional job with our process. We benefited greatly from their industry knowledge, expansive network, deal expertise and just plain hard work. Most importantly, their bankers demonstrated sterling integrity and always gave us sound advice that resulted in an excellent outcome, despite numerous twists and turns along the way.


CEO & Co-Founder, BioAgilytix Labs, Inc.